New artery-delivered combo shows promise against bone cancer
NCT ID NCT06562673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new approach for osteosarcoma (bone cancer) in 10 patients aged 12-40. The treatment combined standard chemotherapy with a targeted drug (Endostar) and cisplatin delivered directly into the artery supplying the tumor. The goal was to see if this method is safe and increases tumor cell death before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital,
Shanghai, 200233, China